Skip to main content
CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. logo

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. — Investor Relations & Filings

Ticker · 000661 ISIN · CNE0000007J8 LEI · 300300X04OTKZG18WD66 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,287 across all filing types
Latest filing 2025-09-15 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000661

About CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD.

https://ccht.jl.cn

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. is a diversified enterprise primarily focused on the research, development, production, and distribution of biopharmaceuticals and healthcare products. The company operates through several key subsidiaries, most notably GeneScience Pharmaceuticals, which specializes in recombinant human growth hormones and pediatric endocrinology treatments. Its product portfolio includes biological drugs, vaccines, and traditional Chinese medicines, targeting therapeutic areas such as growth disorders, infectious diseases, and oncology. The group emphasizes technological innovation and maintains a significant presence in the domestic market while expanding its international footprint. In addition to its core life sciences business, the company maintains interests in real estate development and infrastructure management.

Recent filings

Filing Released Lang Actions
第十一届董事会第十二次会议决议公告
Board/Management Information Classification · 100% confidence The document is an announcement of a board meeting resolution regarding the appointment of a company vice general manager. It details the meeting date, attendance, voting results, and references a related announcement. There is no financial data or report content, only a board/management decision announcement. This fits the category of Board/Management Information (MANG). The document length is short and focused on management changes, not a full report or financial disclosure.
2025-09-15 Chinese
2025年第二次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2025 second extraordinary shareholders meeting of Changchun High-tech Industry (Group) Co., Ltd. It includes voting results on multiple proposals related to the issuance and listing of H shares on the Hong Kong Stock Exchange, amendments to company bylaws, election of independent directors, and other corporate governance matters. The document provides comprehensive voting statistics, meeting details, and legal opinions confirming the validity of the meeting and resolutions. This type of document is a formal declaration of voting results from a shareholders meeting, not a full annual report, earnings release, or management discussion. It is not a proxy solicitation or a report publication announcement. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and detail support a high confidence in this classification.
2025-09-15 Chinese
公司章程（2025年9月修订）
Governance Information Classification · 95% confidence The document is a detailed company charter (章程) for 长春高新技术产业（集团）股份有限公司, including comprehensive sections on company governance, shareholder rights, board structure, and operational rules. It references the company's legal framework, shareholder meetings, board responsibilities, and internal party committee roles. There is no indication that this is an annual report, earnings release, or any financial statement. It is not a brief announcement or a voting result. The document is a governance document detailing the company's internal rules and governance practices. Therefore, it fits the category of Governance Information (CGR). The document length and detail support this classification with high confidence.
2025-09-15 Chinese
董事、高级管理人员薪酬管理办法（2025年9月修订）
Remuneration Information Classification · 95% confidence The document is titled '董事、高级管理人员薪酬管理办法' which translates to 'Remuneration Management Measures for Directors and Senior Management'. It details the principles, structure, and procedures for determining and managing the compensation of the company's directors and senior executives. It includes sections on salary composition, performance evaluation, and approval processes. There is no financial data, audit information, or report publication mentioned. The content is focused on remuneration policies and governance related to executive pay. Therefore, this document fits the category of Remuneration Information (DEF 14A). The document length is 2334 characters, which is consistent with a detailed policy document rather than a brief announcement or report publication.
2025-09-15 Chinese
关于子公司GS3-007a干混悬剂境内生产药品注册临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Changchun High-tech Industry Group Co., Ltd. regarding the acceptance of a clinical trial application for a drug developed by its subsidiary. It details the drug's basic information, clinical trial acceptance by the National Medical Products Administration, and the potential impact on the company. The document is short (1309 characters) and serves as an announcement of regulatory acceptance rather than a financial report or detailed clinical trial results. It does not contain financial data, management changes, or voting results. It is a regulatory announcement about a clinical trial application acceptance, which fits best under Regulatory Filings (RNS) as it does not match other specific categories like Annual Report, Earnings Release, or Legal Proceedings.
2025-09-08 Chinese
关于子公司注射用GenSci140境内生产药品注册临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Changchun High & New Technology Industry Group Co., Ltd. regarding the acceptance of a clinical trial application for a drug developed by its subsidiary. It details the drug's characteristics, the regulatory acceptance by the National Medical Products Administration, and potential impacts and risks. The document is short (1384 characters), does not contain financial data or results, and is an announcement of a regulatory acceptance rather than a financial or management report. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about clinical trial approval, which does not fit other specific categories.
2025-09-05 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.